Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.40 |
| ▸ | NME4 | O00746 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769700 | 0.81 | CA1 (0.46) | CA1CA2MAPK1LMNAL3MBTL1 | |
| SCHEMBL9394417 | 0.80 | BRD4 (0.43) | LMNACYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL7875218 | 0.79 | SMN1; SMN2 (0.43) | LMNACYP1A2CYP2C9CYP2C19ITGB3 | |
| SCHEMBL6654443 | 0.79 | HRH4 (0.48) | MAPK1LMNAL3MBTL1PRSS1CTSG | |
| SCHEMBL9717434 | 0.77 | MAPK1 (0.71) | CA1CA2MAPK1LMNAL3MBTL1 | |
| SCHEMBL22518504 | 0.75 | AOC2 (0.46) | CA1CA2LMNAL3MBTL1CYP1A2 | |
| SCHEMBL4342076 | 0.74 | KMT2A (0.39) | CA1CA2MAPK1CYP1A2CYP2C9 | |
| Betamipron SCHEMBL605899 | 0.73 | PRSS1 (0.70) | CA1CA2MAPK1LMNAPRSS1 | |
| Betamipron SCHEMBL4498475 | 0.73 | PRSS1 (0.70) | CA1CA2MAPK1LMNAPRSS1 | |
| SCHEMBL22306746 | 0.73 | KDM4E (0.36) | CA1CA2LMNAPTGDRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1201740-C | Medicine for treating intermittent claudication containing pyrroloazepine * compound | DAIICHI SUNTORY LTD (JP) | 2005-05-18 | — | — | CN | disclosed |
| EP-1071427-B1 | INTERMITTENT CLAUDICATION THERAPEUTIC DRUGS COMPRISING PYRROLOAZEPINES | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-6713634-B2 | SEROTONIN RECEPTOR ANTAGONIST | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| US-20030166926-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2003-09-04 | — | — | US | disclosed |
| US-6489473-B2 | FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, ARRHYTHMIA, MYOCARDIAL INFARCTION, CONGESTIVE HEART FAILURE, CEREBRAL INFARCTION AND CEREBRAL SEQUELAE AFTER SUBARACHNOID HEMORRHAGE, HYPERTENSION | SUNTORY LIMITED (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020072515-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-0807632-B1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LTD (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-6288056-B1 | ADMINISTERING TO TREAT ATHEROSCLEROSIS IN LEG ARTERIES | SUNTORY LIMITED (JP) | 2001-09-11 | — | — | US | disclosed |
| US-6258805-B1 | TREATMENT OF BRAIN DISORDERS AND HYPERTENSION | SUNTORY LIMITED (JP) | 2001-07-10 | — | — | US | disclosed |
| CN-1297351-A | Medicine for treating intermittent claudication containing pyrroloazepine * compound | SUNTORY LTD (JP) | 2001-05-30 | — | — | CN | disclosed |
| EP-1071427-A1 | INTERMITTENT CLAUDICATION THERAPEUTIC DRUGS COMPRISING PYRROLOAZEPINES | SUNTORY LIMITED (JP) | 2001-01-31 | — | — | EP | disclosed |
| WO-2000048602-A1 | INTERMITTENT CLAUDICATION THERAPEUTIC DRUGS COMPRISING PYRROLOAZEPINES | SUNTORY LIMITED (JP) | 2000-08-24 | — | — | WO | disclosed |
| US-5962448-A | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| EP-0807632-A1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LIMITED (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072515-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | CA1 2654/4885CA2 1009/4885MAPK1 1805/4885 |
| US-20030166926-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | CA1 2756/4885CA2 1098/4885MAPK1 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.